Novo Nordisk ADR (NVO) concluded trading on Wednesday at a closing price of $90.86, with 7.99 million shares of worth about $726.26 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -34.71% during that period and on March 05, 2025 the price saw a gain of about 3.84%. Currently the company’s common shares owned by public are about 3.37B shares, out of which, 3.36B shares are available for trading.
Stock saw a price change of 1.46% in past 5 days and over the past one month there was a price change of 9.93%. Year-to-date (YTD), NVO shares are showing a performance of 5.63% which decreased to -26.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $77.82 but also hit the highest price of $148.15 during that period. The average intraday trading volume for Novo Nordisk ADR shares is 8.87 million. The stock is currently trading 5.55% above its 20-day simple moving average (SMA20), while that difference is up 6.11% for SMA50 and it goes to -21.67% lower than SMA200.
Novo Nordisk ADR (NYSE: NVO) currently have 3.37B outstanding shares and institutions hold larger chunk of about 10.12% of that.
The stock has a current market capitalization of $305.67B and its 3Y-monthly beta is at 0.51. PE ratio of stock for trailing 12 months is 27.68, while it has posted earnings per share of $3.28 in the same period. Its PEG reads 1.46 and has Quick Ratio of 0.55 while making debt-to-equity ratio of 0.72. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVO, volatility over the week remained 1.87% while standing at 2.40% over the month.
Stock’s fiscal year EPS is expected to rise by 21.06% while it is estimated to increase by 23.82% in next year. EPS is likely to shrink at an annualized rate of 19.00% for next 5-years, compared to annual growth of 21.74% made by the stock over the past 5-years.
On January 06, 2025, Bernstein Upgrade their recommendations, while on May 30, 2024, Goldman Initiated their ratings for the stock with a price target of $156. Stock get an Outperform rating from BMO Capital Markets on April 12, 2024.
